Abstract
The publication outlines the results of antigenic activity trials for experimental samples of a marker vaccine against classical swine fever (CSF) prepared using different types of adjuvants, as well as data on the duration of immunity upon administration of this vaccine to laboratory and naturally susceptible animals. Live vaccine “KS”, widely used for the specific prophylaxis of CSF in Russia, was used as positive control. The data obtained indicate that all experimental samples of the vaccines stimulated a pronounced immune response to CSF viral glycoprotein E2, triggering off production of virus-neutralising antibodies in immunised piglets. Antibodies possessing such specificity were detected in piglets in high concentrations over a period of 96 days after double vaccination up to the final day of the experiment. Experimental samples of the vaccine did not induce synthesis of antibodies to CSF viral glycoprotein ЕRNS, which would allow one to use the vaccine and be able to distinguish vaccinated animals from those naturally infected with field strains. This strategy, by consequence, will be valuable in the implementation of CSF eradication programs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
